The Russian Direct Investment Fund (RDIF) and have signed agreements with Indian vaccine and pharmaceutical producer Panacea Biotec and Chinese TopRidge Pharma on cooperation in production of Sputnik V anti-coronavirus vaccine. According to each agreement, it is planned to produce 100 mln doses per year. The amount of the vaccine that is produced by each company will be sufficient to inoculate over 50 mln people.
TopRidge Pharma will be able to distribute the vaccine in mainland China, as well as in Hong Kong, Macao and Taiwan, subject to all appropriate regulatory approvals. The parties also intend to cooperate on clinical trials of the vaccine in China and promotion of Sputnik V in the country.
Cooperation with Panacea Biotec is an important step to produce the vaccine in India and to supply international partners around the world. "Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF," the Fund explained.
To date Sputnik V has been registered in 59 countries globally with total population of over 1.5 bln people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals.
Ministry of Industry
and Trade of Russia
and Trade of Russia